Icosavax Mourns Sudden Passing of Tadataka Yamada, M.D. Chairman of the Company’s Board of Directors
05 août 2021 08h00 HE
|
Icosavax, Inc.
SEATTLE, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Respiratory Syncytial Virus Infection Pipeline: Insights into Clinical Trial Landscape, Key Pharma Players, Emerging Therapies with Novel MoAs, and Dynamics Shaping the Pipeline Landscape | DelveInsight
02 août 2021 20h00 HE
|
DelveInsight Business Research LLP
Los Angeles, USA, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Respiratory Syncytial Virus Infection Pipeline: Insights into Clinical Trial Landscape, Key Pharma Players, Emerging Therapies with Novel MoAs,...
Icosavax Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
02 août 2021 16h01 HE
|
Icosavax, Inc.
SEATTLE, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Respiratory Syncytial Virus Therapeutics Market worth USD 4,003.4 Million at 30.9% CAGR; Varying Ethnicity and Climate Difference to Boost Demand in Asia Pacific
20 janv. 2021 08h42 HE
|
Fortune Business Insights
Pune, India, Jan. 20, 2021 (GLOBE NEWSWIRE) -- The global Respiratory Syncytial Virus Therapeutics Market size is estimated to showcase potential growth owing to its increasing adoption against the...